169 related articles for article (PubMed ID: 21532882)
1. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.
Starlinger P; Brugger P; Schauer D; Sommerfeldt S; Tamandl D; Kuehrer I; Schoppmann SF; Gnant M; Brostjan C
Neoplasia; 2011 May; 13(5):419-27. PubMed ID: 21532882
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
3. Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Vizio B; Novarino A; Giacobino A; Cristiano C; Prati A; Brondino G; Ciuffreda L; Bellone G
Cancer Sci; 2010 Nov; 101(11):2448-54. PubMed ID: 20950371
[TBL] [Abstract][Full Text] [Related]
4. Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization.
Yu JX; Huang XF; Lv WM; Ye CS; Peng XZ; Zhang H; Xiao LB; Wang SM
J Vasc Surg; 2009 Sep; 50(3):608-16. PubMed ID: 19595531
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Nixon AB; Pang H; Starr MD; Friedman PN; Bertagnolli MM; Kindler HL; Goldberg RM; Venook AP; Hurwitz HI;
Clin Cancer Res; 2013 Dec; 19(24):6957-66. PubMed ID: 24097873
[TBL] [Abstract][Full Text] [Related]
6. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Ko AH; Dito E; Schillinger B; Venook AP; Xu Z; Bergsland EK; Wong D; Scott J; Hwang J; Tempero MA
Invest New Drugs; 2008 Oct; 26(5):463-71. PubMed ID: 18379729
[TBL] [Abstract][Full Text] [Related]
7. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.
Starlinger P; Brugger P; Reiter C; Schauer D; Sommerfeldt S; Tamandl D; Kuehrer I; Schoppmann SF; Gnant M; Brostjan C
Neoplasia; 2011 Oct; 13(10):980-90. PubMed ID: 22028623
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Sahora K; Schindl M; Kuehrer I; Eisenhut A; Werba G; Brostjan C; Telek B; Ba'ssalamah A; Stift J; Schoppmann SF; Gnant M
Anticancer Res; 2014 May; 34(5):2377-84. PubMed ID: 24778046
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Kindler HL; Friberg G; Singh DA; Locker G; Nattam S; Kozloff M; Taber DA; Karrison T; Dachman A; Stadler WM; Vokes EE
J Clin Oncol; 2005 Nov; 23(31):8033-40. PubMed ID: 16258101
[TBL] [Abstract][Full Text] [Related]
10. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Shaked Y; Henke E; Roodhart JM; Mancuso P; Langenberg MH; Colleoni M; Daenen LG; Man S; Xu P; Emmenegger U; Tang T; Zhu Z; Witte L; Strieter RM; Bertolini F; Voest EE; Benezra R; Kerbel RS
Cancer Cell; 2008 Sep; 14(3):263-73. PubMed ID: 18772115
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis.
Hoenig MR; Bianchi C; Sellke FW
Curr Drug Targets; 2008 May; 9(5):422-35. PubMed ID: 18473772
[TBL] [Abstract][Full Text] [Related]
12. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
13. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
15. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization.
Hiasa K; Ishibashi M; Ohtani K; Inoue S; Zhao Q; Kitamoto S; Sata M; Ichiki T; Takeshita A; Egashira K
Circulation; 2004 May; 109(20):2454-61. PubMed ID: 15148275
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
Wakelee H
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S113-8. PubMed ID: 18520292
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor promoted endothelial progenitor cell mobilization into the peripheral blood of a patient with POEMS syndrome.
Rosti V; Massa M; Campanelli R; De Amici M; Piccolo G; Perfetti V
Haematologica; 2007 Sep; 92(9):1291-2. PubMed ID: 17768134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
